Median arcuate ligament syndrome: MALS, celiac compression and abdominal pain

Median arcuate ligament syndrome concerns otherwise unexplained symptoms associated with external compression near the celiac artery. A compressed-looking artery can be incidental. Diagnosis and treatment selection need a specialist assessment that considers other causes of abdominal pain.

Table of contents

• Evidence summary: symptomatic MALS is more than arterial indentation
• What are MALS, the median arcuate ligament and the celiac artery?
• Vascular and nerve mechanisms remain debated
• Selected ligament release and the limits of primary stenting
• No supplement is an established treatment for ligament compression
• Nutrition, symptom support and care for other contributors
• Severe abdominal pain, bleeding and operative hazards
• Painkillers, contrast and procedure-related medicines
• Respiratory imaging and exclusion of other abdominal disease
• Follow-up, persistent symptoms and unusual collateral aneurysms
• A planned controlled trial is different from proven effectiveness
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary: symptomatic MALS is more than arterial indentation

Median arcuate ligament syndrome (MALS), also called Dunbar syndrome or celiac artery compression syndrome, concerns otherwise unexplained symptoms associated with external compression near the celiac artery. Anatomical indentation can be incidental, so a scan alone does not establish the diagnosis or a need for surgery.

The original 2022 systematic review found substantial variation in diagnostic definitions and patient outcomes, with high or unclear bias in most included studies. A formal meta-analysis was not appropriate. Its search ended in July 2021; reported improvement cannot be turned into a precise personal success rate. original review and limits.

CARoSO compares endoscopic release with a sham operation. The official registry’s March 2026 update records recruitment and has no posted results. That is a recorded status, not an October recruitment check or an efficacy finding. actual registry record.

What are MALS, the median arcuate ligament and the celiac artery?

A fibrous diaphragmatic arch can compress the celiac artery dynamically, often more during expiration; the nearby nerve plexus may be involved. July 2026 anatomical review.

Celiac artery refers to a blood vessel. Coeliac disease is a different gluten-related immune condition affecting the small intestine. Their similar names should not lead to a gluten-free diet being presented as treatment for arterial compression. dated public disease distinction.

Ask whether the clinician is describing an anatomical finding or a clinically established syndrome. Keep the report and have the involved artery explained. A striking image needs to be interpreted with symptoms and other investigations rather than treated as a self-contained diagnosis.

Vascular and nerve mechanisms remain debated

Altered arterial supply and nerve irritation are possible contributors. Restored anatomy and pain relief do not correspond perfectly, leaving mixed mechanisms plausible. current mechanistic assessment.

The uncertainty matters when choosing outcomes. Ask whether the proposed care targets mechanical compression, a nerve component, nutrition or another contributor to pain. If a nerve block is offered, request an explanation of what a temporary response would establish and what it would leave uncertain.

A mechanistic explanation should account for the symptom pattern rather than only the image. Relief during one test does not itself guarantee durable surgical benefit. The clinical plan should state how uncertainty affects the recommendation and what evidence could change it.

Selected ligament release and the limits of primary stenting

The 2025 ESVS guideline supports multidisciplinary selection and allows surgery in selected patients. It favors a release-first approach over placing a stent into an artery still subject to external compression. Further revascularization is considered selectively for persistent symptoms with relevant residual disease. original treatment framework.

Ligament release aims to remove the external constraint; the extent of nerve treatment and the operative approach need explanation. Ask why the proposed technique suits the anatomy and what would prompt conversion or arterial reconstruction. A label such as robotic does not establish better long-term patient benefit.

Request a comparison of observation, symptom care and the proposed operation for the actual clinical presentation. Consent should address the possibility of persistent pain, later investigation and further treatment. This review supplies no personal indication, operation choice or independent surgical-platform ranking.

No supplement is an established treatment for ligament compression

This review establishes no supplement, detox, enzyme product or circulation remedy as a replacement for diagnostic assessment or a specialist MALS plan. A product’s laboratory effect on inflammation does not show that it releases the ligament or provides lasting patient benefit.

Disclose all vitamins, herbal products and supplements before pain medicines, imaging, a nerve block or surgery. Natural origin does not establish safety, and interactions can occur. NIH’s linked information is dated January 2019 and supports precautions rather than MALS efficacy. dated supplement-safety context.

Nutritional replacement for a documented deficiency is a different clinical goal from treating arterial compression. Ask what deficiency or intake problem a proposed nutritional product addresses, who will review it, and which medicines or tests it might affect. This article supplies no supplement regimen.

Nutrition, symptom support and care for other contributors

Unintentional weight loss can have several causes and deserves assessment, especially when accompanied by other symptoms. It should not be assigned automatically to MALS after an incidental scan finding. The clinical team needs to investigate the weight change and its consequences. July 2025 public assessment advice.

When intake is inadequate, a dietitian can assess nutritional needs. Some patients need fortified food, nutritional drinks or other support chosen for their circumstances. This is care for undernutrition, not proof of a MALS-specific diet. The linked NHS page is dated May 2023. dated nutrition-care context.

Make the plan practical: ask how to maintain intake while pain is investigated, how weight and strength will be reviewed, and which team coordinates symptom support. Avoid progressively restricting foods without a clinical explanation. A care plan should address the burden of symptoms while diagnostic and treatment questions remain open.

Severe abdominal pain, bleeding and operative hazards

Sudden severe abdominal pain, a tender abdomen, vomiting blood, black sticky stool, inability to pass urine or stool/gas, breathing difficulty or collapse can require emergency care. Do not drive yourself to emergency care. A chronic MALS label does not explain these new changes automatically. dated public emergency advice.

The 2026 review describes operative hazards including vascular injury and bleeding. original complication discussion.

Ask about the team’s plan for complications, procedure-specific warning signs and the contact route after discharge. The size of an incision does not explain the entire clinical risk.

If blood-thinning treatment is prescribed, significant bleeding, blood in urine or stool, persistent bleeding or a head injury needs urgent advice. Tell the urgent-care team the medicine and recent procedure. public medicine-safety information.

Painkillers, contrast and procedure-related medicines

Regular anti-inflammatory painkiller use can cause stomach ulcers. Ulcer symptoms can overlap with abdominal complaints but require a different assessment and treatment pathway. Check painkiller use with the clinician rather than escalating it while persistent upper abdominal pain remains unexplained. August 2025 public ulcer information.

If anticoagulation is prescribed for a separate indication or procedure plan, check other prescriptions, painkillers and herbal products. Pregnancy and operations require medicine-specific advice. Do not add or stop a blood thinner yourself. public interaction considerations.

People actually taking clopidogrel also need checks for interacting medicines and supplements. Kidney function and contrast exposure need review before relevant imaging. clopidogrel-specific precautions; renal-safety context. This guide does not determine which medicine to suspend.

Respiratory imaging and exclusion of other abdominal disease

The ESVS guideline recommends mesenteric duplex during inspiration and expiration and specialist multidisciplinary assessment. It reserves the diagnosis for highly selected patients with otherwise unexplained symptoms and relevant external compression. Its specified measurements are not a home diagnostic rule. original diagnostic framework.

Stomach ulcers, for example, can produce upper abdominal pain, nausea or vomiting and may require investigation for H pylori or gastroscopy. Other plausible causes should be evaluated according to the presentation rather than dismissed because a vascular image looks abnormal. distinct diagnostic pathway.

Ask what each test will establish and whether it could change the recommendation. Bring the full clinical history, earlier imaging and results of gastrointestinal assessment. Explain the relationship to meals and activity, any food avoidance and the effect on daily function. These details support clinical discussion without becoming an online diagnostic checklist.

Follow-up, persistent symptoms and unusual collateral aneurysms

Agree on the outcomes to review: pain, ability to eat, weight trajectory and function, as well as the treated anatomy. A postoperative image and meaningful recovery are different findings. Ask who will reassess persistent symptoms and how another procedure would be justified.

A 2025 case report describes collateral-artery aneurysms alongside presumed chronic MALS-related occlusion. It illustrates a distinct complex anatomical presentation, not the usual natural history or proof that every incidental compression needs early surgery. original single-case scope.

Keep the procedure summary, imaging reports and medicine plan. If an aneurysm or another vascular lesion is present, ask which problem determines urgency and how organ blood supply will be preserved. The report of one successful technical strategy does not establish a universal plan for a different patient.

A planned controlled trial is different from proven effectiveness

Cell, animal and flow models cannot establish durable relief of pain, restoration of intake or quality-of-life benefit from surgery or a supplement. Human evidence must address symptom outcomes and competing explanations as well as anatomy.

The original CARoSO protocol describes a sham-controlled research question and identifies Promising Care funding. Its assumptions and projected gains are not results. original protocol and funding. The funder’s project page confirms subsidy and a later Dutch coverage assessment; that jurisdiction-specific process does not establish effectiveness today. actual grant and decision status.

Manufacturer-funded or supplied-product efficacy is excluded from the independent verdict. Public grants do not automatically clear investigator, hospital, publication or additional private resource chains. Unknown finances stay visible.

Funding and source roles

The 2026 academic review declares no submitted-work support or relevant financial relationships, without clearing employer or publication resources. The 2022 systematic pre-proof reports no specific grant but does not supply a complete author register. ESVS development support and individual disclosures remain separate. CARoSO’s original protocol and actual grant page name Promising Care support; current program rules allow some private resources, which does not establish a specific maker grant. The trial sponsor is a hospital, not the US registry host.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Does a hooked or compressed artery on CT establish MALS?
No. Relevant symptoms, dynamic assessment and exclusion of other causes are required.

Is MALS the same as coeliac disease?
No. One concerns external compression near an artery; the other is a gluten-related immune disease.

Does a less invasive operation guarantee lasting relief?
No. Operative access and long-term patient outcomes are different measures.

Is the CARoSO registry an efficacy result?
No. Its March 2026 record has no posted results.

Does an aneurysm case prove every incidental compression needs surgery?
No. It describes a different, complex presentation and does not establish general risk.

Sources and funding notes

The full current narrative review, accepted systematic pre-proof, ESVS MALS chapter, single-case original and CARoSO protocol were opened. The official registry API was read: March 16,2026 last posted update, recruiting recorded, no posted results. No October recruitment verification or published randomized outcome is claimed. The program ended new applications in January 2026 while ongoing studies remained unchanged. Project/grant dates and participant-enrolment dates are different. Dutch reimbursement status is not a universal clinical prohibition or another jurisdiction’s coverage decision.

• Gotti and colleagues: original July 2026 MALS review — Anatomy, mechanisms, complications and limits; no surgical-platform ranking.
• Metz and colleagues: original 2022 systematic review — Patient outcomes and evidence limitations; no pooled efficacy recommendation.
• ESVS: original 2025 mesenteric/renal guideline — Multidisciplinary selection, respiratory imaging and release-first context; no automatic stent indication.
• Manchella and colleagues: original 2025 case report — Collateral-aneurysm pathway as a distinct presentation, not general natural-history risk.
• CARoSO: original 2022 protocol letter — Sham-controlled research question only; assumptions are not efficacy findings.
• CARoSO: actual ClinicalTrials.gov registry — Recorded trial status and absence of posted results only.
• Zorginstituut Nederland: actual CARoSO grant/project page — Funding and jurisdiction-specific reimbursement status; no demonstrated clinical efficacy.
• Zorginstituut Nederland: governmental remit — Funder identity, not an independence certificate for all trial authors.
• Zorginstituut Nederland: current subsidy rules — Current program finance limits, separate from specific project money.
• NHS: stomach ache (May 2023) — Severe pain, bleeding, collapse and other urgent changes; past stated 2026 review.
• NHS: unintentional weight loss (July 2025) — Weight-loss assessment and several possible causes.
• NHS: malnutrition (May 2023) — Dietitian-led nutrition support; past stated 2026 review, no MALS-specific diet.
• NHS: coeliac disease (March 2023) — Different gluten-related immune disease; past stated 2026 review.
• NHS: stomach ulcer (August 2025) — Competing pain cause, NSAID risk and distinct diagnostic/treatment pathway.
• NHS: acute kidney injury (March 2026) — Contrast and renal/medicine planning only.
• NHS: anticoagulant side effects (September 2024) — Bleeding and injury precautions only.
• NHS: anticoagulant considerations (September 2024) — Exact medicine, pregnancy and procedure planning; no personal regimen.
• NHS: clopidogrel interactions (March 2025) — Only if actually prescribed in a MALS-related vascular procedure plan; medicine/supplement interaction context, not a routine treatment recommendation.
• NCCIH: supplement safety (January 2019) — Disclosure and interaction precautions only.
• ESVS: EVeR registry support — Institutional funding route only.
• ESVS: administrative contact — Office trace only.
• NHS website: content and funding policy — Website funding and editorial safeguards only.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.